公开(公告)号：US20230027495A1

公开(公告)日：2023-01-26

申请号：US17775279

申请日：2020-11-06

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/36 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US11492371B2

公开(公告)日：2022-11-08

申请号：US16426647

申请日：2019-05-30

Applicant: GENMAB A/S

Inventor： Michael Gramer ,  Amitava Kundu ,  Ewald T. J. Van Den Bremer ,  Muriel Van Kampen ,  Patrick Priem ,  Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Janine Schuurman ,  Paul Parren ,  Patrick Van Berkel ,  Werner L. Vos ,  Arnout F. Gerritsen

IPC: C07K1/113 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.

公开(公告)号：US11359015B2

公开(公告)日：2022-06-14

申请号：US15744317

申请日：2016-07-14

Applicant: GENMAB A/S

Inventor： Rik Rademaker ,  Isil Altintas ,  Patrick Engelberts ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20220144964A1

公开(公告)日：2022-05-12

申请号：US17559938

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian ELLIOTT ,  Tahamtan AHMADI ,  Christopher W. L. CHIU ,  Esther C. W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28 ,  A61K31/454

Abstract: Provided are methods of clinical treatment of follicular lymphoma (for example, relapsed and/or refractory follicular lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimens of rituximab and lenalidomide.

公开(公告)号：US20220133721A1

公开(公告)日：2022-05-05

申请号：US17346851

申请日：2021-06-14

Applicant: GENMAB A/S

Inventor： Daniel Simon PEEPER ,  Judith Nadja MUELLER

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/437 ,  A61K31/519 ,  A61K31/502 ,  C12Q1/6886 ,  G01N33/574

Abstract: The current disclosure relates to pharmaceutical combinations and compositions useful in the treatment of certain types of cancer. The disclosure also relates to methods for treatment of these types of cancer. In particular, the disclosure relates to the combined use of of an inhibitor of a protein of the MAPK/ERK pathway and an inhibitor of specific kinases in the treatment of a cancer, in particular melanoma, in a patient. In an important embodiment, the cancer is characterized by the absence or reduced expression of MITF.

公开(公告)号：US20220112287A1

公开(公告)日：2022-04-14

申请号：US17559935

申请日：2021-12-22

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Jenny Jianlin CHEN ,  Tahamtan AHMADI ,  Christopher W.L. CHIU ,  Esther C.W. BREIJ ,  Ida HIEMSTRA ,  Maria N. JURE-KUNKEL

IPC: C07K16/28

Abstract: Provided are methods of clinical treatment of chronic lymphoblastic leukemia (CLL) in human subjects using a bispecific antibody which binds to CD3 and CD20.

公开(公告)号：US20220088191A1

公开(公告)日：2022-03-24

申请号：US17053753

申请日：2019-05-07

Applicant: Genmab A/S ,  MSD International GmbH

Inventor： Reshma Abdulla RANGWALA ,  Esther C.W. BREIJ ,  Sandra VERPLOEGEN ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Anthony CAO ,  Shyra GARDAI

IPC: A61K39/395 ,  A61K47/68 ,  A61P35/00

Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.

公开(公告)号：US11261254B1

公开(公告)日：2022-03-01

申请号：US17494545

申请日：2021-10-05

Applicant: GENMAB A/S

Inventor： Louise Koopman ,  Patrick Engelberts ,  Dennis Verzijl ,  Edward N. Van Den Brink ,  Rik Rademaker ,  Sieto Bosgra ,  Frederikke L. Egerod ,  David Satijn ,  Esther C. W. Breij

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20210402003A1

公开(公告)日：2021-12-30

申请号：US17289616

申请日：2019-10-28

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Sandra VERPLOEGEN ,  Esther C.W. BREIJ ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/22 ,  C07K16/36 ,  A61K9/00 ,  A61K45/06 ,  A61K39/395

Abstract: The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such cervical cancer. The invention also provides compositions and kits comprising the anti-VEGF antibody (e.g., bevacizumab) and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as cervical cancer.

公开(公告)号：US20210395384A1

公开(公告)日：2021-12-23

申请号：US17198199

申请日：2021-03-10

Applicant: Genmab A/S

Inventor： David SATJIN ,  Sandra VERPLOEGEN ,  Wim BLEEKER ,  Steen LISBY ,  Jan VAN DE WINKEL ,  Patrick VAN BERKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/36 ,  A61K47/68 ,  A61K45/06

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.